Fig. 8

USP7 blockade halts the capacity of tolerogenic Stat5b-CA.DCs to protect NOD mice from diabetes. Purified splenic DC of NOD and NOD.Stat5b-CA mice were treated or not with USP7 inhibitor P5091 (5 µM/mL, for 24 h), stimulated with LPS for another 24 h, and intravenously injected into 3–4 weeks old female NOD mice (7 mice per group, 6 × 10⁶ cells/mouse). Recipient NOD mice were followed for diabetes development until 32 weeks of age. For comparison of diabetes incidence between different groups, the Gehan–Breslow–Wilcoxon test was performed to calculate the significant difference. n.s., not significant; ****P < 0.0001